June 20, 2019
Cyxone starts in-human testing of its multiple sclerosis drug candidate
Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).